Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0582-0001 in healthy volunteers
NCT05624580Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2022
- Primary completion
- Oct 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0582-0001 (7 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events at 52 weeks. Started Nov 2022; status: completed.
02
Drugs
NNC0582-0001
Beyond the preview
Go deeper on NCT05624580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624580.